The science behind Geno360Health Genetic Testing
Genetic testing is emerging as a central tool in modern healthcare. No longer confined to the diagnosis of rare diseases in specialized laboratories, it is increasingly used to guide medication selection and dosing, stratify risk for common chronic conditions, and support more efficient, personalized care.
Genetic testing is not limited to terminal illnesses or lifelong disorders. By
translating individual genomic data into interpretable risk and response profiles, it can inform scientifically grounded health decisions at the individual patient level (Scott et al., 2014). As healthcare moves toward precision medicine, genetic testing enables clinicians to move beyond symptom-based diagnosis and traditional treatment models toward mechanisms-informed, preventive, and personalized care strategies.
Georgia Healthcare Centre’s commitment to longevity and preventative health is reflected in its offering of the comprehensive Geno360Health service, a comprehensive genetic DNA test that harnesses germline genetic testing. For clinicians, this testing can be particularly valuable because it minimizes time-consuming approaches such as trial-and-error prescribing and ultimately
provides more precise insight into a patient’s unique inherited health profile.
Similar to the way a family history is used to infer inherited risk for certain diseases, Geno360Health interrogates specific genetic variants associated with medication response, disease susceptibility, and other health-related traits, ultimately reducing reliance on assumptions about a patient’s predispositions.
This may be especially informative for individuals with limited or no knowledge of their family medical history, for whom genetic data can complement, but not replace, traditional risk assessment.
One key way clinicians can use Geno360Health results is to better understand how a patient’s genetic profile may influence their response to certain medications. Currently, in most cases, medicine is prescribed to patients in a standardized manner for individual medical conditions, with the same dose of the same medication as a starting point. Genetic testing’s ability to identify the
genetic makeup that may cause a patient to respond differently to a medication can avoid undesirable side effects from medication, weakened effects of the medication, and unnecessary health care costs and wasted time (Scott et al., 2014).
Pharmacogenetics is the study of how inherited DNA differences influence an individual’s response to medication, including its effectiveness, metabolism, required dose, or risk of adverse effects. A pharmacogenetic variant is
a specific inherited DNA sequence that has been shown to alter one or more of these medication responses (Scott et al., 2014). For example, patients taking oral anticoagulants, such as warfarin, for conditions such as venous thromboembolism were found to have highly variable dose requirements due to genetic variants of the genes CYP2C9 and VKORC1, two genes that are tested
for in Geno360Health. These genes influence how warfarin is metabolized and how strongly it affects the body.
In a 2026 study (Fahmi et al., 2026), a genotype-guided warfarin dosing model
was developed and validated in a mixed Arab population. The genetic variants previously listed, combined with clinical factors such as age, weight, interacting medications, etc., were responsible for more than 50% of warfarin dose variability and produced more accurate dose predictions than an internationally used model that did not consider genotype, supporting precise, individualized
dosing (Fahmi et al., 2026).
In additional retrospective studies, pharmacogenetically guided dosing
has been shown to improve the accuracy of initial dose selection compared with fixed-dose approaches and the warfarin label dosing table, although subsequent clinical monitoring remains necessary (Scott et al., 2014). When clinically validated results are available, they can help healthcare professionals consider whether additional monitoring, dose adjustment, or an alternative medication may be appropriate.
Another clinically important application of Geno360Health, pertaining to both men and women, is the assessment of hereditary susceptibility to breast and ovarian cancer due to pathogenic variants of the BRCA1 and BRCA2 genes, which encode tumor suppressor proteins essential for DNA repair and genome stability (Sherigar et al., 2026). Geno360Health reports whether an individual carries known pathogenic or likely pathogenic variants in BRCA1/2. These variants
follow an autosomal dominant, monogenic inheritance pattern; each child of a carrier has a 50% chance of inheriting the altered allele. Carrying a BRCA1 or BRCA2 variant does not guarantee that an individual will develop cancer, but it confers a substantially elevated lifetime risk, with additional somatic alterations typically required to initiate tumor formation.
Large cohort and population studies estimate that female carriers of pathogenic BRCA1/2 variants face roughly 45%–80% lifetime risk of breast cancer and 15%–45% lifetime risk of ovarian cancer, compared with about 3% and <1%, respectively, in the general population. Male carriers also have increased risks, including male breast and prostate cancer. In practice, a positive result may prompt referral
for genetic counselling, initiation of enhanced breast screening protocols (such as earlier and more frequent imaging, including breast MRI), and discussion of risk‑reducing options, including pharmacologic prevention and, where appropriate, risk‑reducing mastectomy and salpingo‑oophorectomy (Sherigar et al., 2026). By clarifying inherited risk before disease onset, this approach shifts the focus from reactive, symptom‑driven care to proactive, preventive health
management. Individuals can use this information to plan long‑term surveillance, make informed lifestyle and reproductive decisions, and engage with their care team in a structured, evidence‑based prevention pathway.
In addition to genetic testing for medication response and cancer-associated genes, Geno360Health can provide information about inherited influences on nutrition, skin health, and other complex human traits. Human pigmentation is a complex polygenic trait influenced by variants in genes involved in melanin production and transport, including MC1R and SLC45A2; these genetic
effects interact with UV exposure, age, lifestyle, and other environmental factors (Bose et al.,2026). Similarly, variants affecting skin-barrier function, including variants in FLG, have been associated with susceptibility to atopic dermatitis, while multiple immune-related loci contribute to psoriasis risk (Yang, 2025). These findings represent statistical predispositions rather than diagnostic results: carrying an associated variant does not establish that a person has, or will
necessarily develop, a particular dermatological condition.
Instead, the results may help individuals understand aspects of their baseline biology and make more informed decisions regarding sun protection, skincare, nutrition, and other preventive health behaviours.
For example, a person with genetically influenced increased UV sensitivity may benefit from consistent photoprotection, including sunscreen use, protective clothing, and avoidance of excessive sun exposure (Yang, 2025). For individuals seeking a more specialized assessment of aesthetic and dermatological predispositions, Georgia Healthcare Centre also offers the GenoBeauty service.
Geno360Health uses genetic testing that has NABL accreditation, CAP accreditation, and ISO 15189 certification, holding the test to global standards of laboratory quality and competence (Mapmygenome, n.d.). Together, these accreditations indicate that the laboratory operates under a formal quality management system, participates in ongoing external quality assessment, and is
subject to regular audits to maintain compliance. For patients and clinicians, this provides greater confidence that Geno360Health results are generated using validated methods, with appropriate controls and oversight, and are therefore suitable to inform clinical discussions and preventive health planning.
Geno360Health illustrates how germline genetic testing can be integrated into routine, preventive, and personalized care. By combining pharmacogenetic insights, hereditary cancer risk assessment, and trait-related information within an accredited laboratory framework, the service provides clinicians and patients with additional data to complement traditional examinations. When interpreted by qualified healthcare professionals and used alongside established clinical guidelines, these results can support more targeted prevention strategies, more efficient medication management, and more informed health decisions throughout the stages of a patient’s life.
For individuals with specific clinical questions or a strong family history of a particular condition
Specialized genetic testing options that allow for deeper,
condition-focused evaluation beyond the scope of the Geno360Health panel.
Author: Erin Greene
Clinical Research Analyst with an MSc. in Statistics with Medical Applications from the University of Sheffield. She has experience working with real-world health datasets and clinical trial data, using tools such as R to derive clinically meaningful results such as treatment effectiveness.
References
Bose, A., Sengupta, M., Maitra, S., Bandyopadhyay, A. R., & Schaschl, H. (2026). The genetic architecture of human skin pigmentation: evolution and adaptation across global populations. Frontiers in Genetics, 17, 1870791.
Fahmi, A. M., Bardissy, A. E., Saad, M. O., Eljilany, I., Bader, L., & Elewa, H. (2026).
Derivation and validation of a genotype- guided Warfarin dosing model in a mixed Arab population. Clinical and Applied Thrombosis/Hemostasis, 32, 10760296261439536.
Mapmygenome. (n.d.). Accreditations & Quality Standards | NABL & CAP certified -
Mapmygenome.
Scott, S., Abul-Husn, N., Obeng, A. O., Sanderson, S., & Gottesman, O. (2014). Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics and Personalized Medicine, 7, 227. https://doi.org/10.2147/pgpm.s48887
Sherigar, P., Herga, S. K., Pai, A., Mailankody, S., & Udupa, K. S. (2026). Recent advances in genetic testing and clinical management of hereditary breast and ovarian cancer (HBOC) in India. Cancer Medicine, 15(7), e71497. https://doi.org/10.1002/cam4.71497
Yang, J. (2025). Personalized skin health management and nutrition strategies: a comprehensive study based on genetic polymorphisms and dietary factors. Frontiers in Genetics, 16,1624960. https://doi.org/10.3389/fgene.2025.1624960
Comments